Van Diest Capital LLC Makes New $788,000 Investment in IQVIA Holdings Inc. $IQV

Van Diest Capital LLC acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, HoldingsChannel.com reports. The fund acquired 3,494 shares of the medical research company’s stock, valued at approximately $788,000. IQVIA accounts for approximately 1.2% of Van Diest Capital LLC’s investment portfolio, making the stock its 18th largest position.

Several other hedge funds also recently made changes to their positions in IQV. Compound Planning Inc. bought a new stake in shares of IQVIA in the 4th quarter worth approximately $312,000. Harbour Wealth Management Group Inc. acquired a new stake in IQVIA during the fourth quarter valued at approximately $660,000. First Growth Capital LLC bought a new stake in IQVIA during the fourth quarter worth approximately $474,000. Corient Private Wealth LLC grew its position in IQVIA by 106.6% in the fourth quarter. Corient Private Wealth LLC now owns 26,803 shares of the medical research company’s stock worth $6,042,000 after buying an additional 13,828 shares during the last quarter. Finally, CrossGen Wealth LLC bought a new position in shares of IQVIA in the fourth quarter valued at $28,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 1.5%

IQVIA stock opened at $168.14 on Friday. IQVIA Holdings Inc. has a 52 week low of $153.01 and a 52 week high of $247.04. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a market capitalization of $28.06 billion, a price-to-earnings ratio of 20.84, a P/E/G ratio of 1.46 and a beta of 1.21. The company has a 50 day moving average price of $173.72 and a 200 day moving average price of $191.84.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company’s revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the business earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA declared that its Board of Directors has authorized a share repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on IQV. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday, June 14th. Evercore reaffirmed an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th. Royal Bank Of Canada began coverage on IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price for the company. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a research report on Wednesday. Finally, Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target on the stock in a research note on Friday, March 6th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $222.56.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.